We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial.
- Authors
Verdejo, Hugo E.; Rojas, Adolfo; López-Crisosto, Camila; Baraona, Fernando; Gabrielli, Luigi; Maracaja-Coutinho, Vinicius; Chiong, Mario; Lavandero, Sergio; Castro, Pablo F.
- Abstract
Background: Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers. Conclusions: A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.
- Subjects
PULMONARY artery; RANDOMIZED controlled trials; VENTRICULAR remodeling; TRIMETAZIDINE; PULMONARY hypertension; TREADMILL exercise; RIGHT ventricular hypertrophy
- Publication
Journal of Clinical Medicine, 2023, Vol 12, Issue 4, p1571
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm12041571